RxDoctor Payments Data

Efua Asamoah-Odei, MD

Nephrology · Phila, PANPI 1043479082

Payments from drug & device makers

$2,945in general payments, 2019–2025

Across 168 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$499
  • AstraZeneca$497
  • Vifor Pharma, Inc.$403
  • Amgen$396
  • OPKO Pharmaceuticals, LLC$261
  • Calliditas Therapeutics US Inc.$170
  • plus $720 from 10 others

What the payments were for

  • Food & beverage$2,82096%
  • Education$1254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,945 in reported general payments places this provider in the 75th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$199,978
Medicare patients
457
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin187$139,441
FarxigaDapagliflozin Propanediol112$79,561
VelphoroSucroferric Oxyhydroxide27$52,710
KerendiaFinerenone46$38,505
VeltassaPatiromer Calcium Sorbitex31$24,729
EntrestoSacubitril/Valsartan21$18,240
LokelmaSodium Zirconium Cyclosilicate16$13,388
JanuviaSitagliptin Phosphate14$11,659
Sevelamer Carbonate91$10,448
Lanthanum Carbonate16$10,339
Calcitriol268$3,205
Calcium Acetate43$1,664
Nifedipine ErNifedipine53$1,650
Losartan Potassium152$1,589
Bumetanide79$1,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$73$139,441187 claims
AstraZenecaFarxiga, Lokelma$497$92,950128 claims
Fresenius USA Marketing, Inc.Velphoro$170$52,71027 claims
BayerKerendia$499$38,50546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →